01 Aug 2026

CRC Research Update — August 01, 2026

Creator: The CRC Digest
Published: 2026-08-01T11:41:37Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
HER2-mutated colorectal cancers show distinct genomic features from HER2-amplified tumors
Analysis of 4,348 CRC patients found that ERBB2/HER2 mutations occurred in 2.2% and amplifications in 2.0%, with distinct genomic landscapes and clinical characteristics between the two groups. (Oncologist)
TRIAL DATA
Meta-analysis examines timing of chemotherapy after colorectal cancer surgery
A systematic review and meta-analysis evaluated the impact of early versus delayed postoperative chemotherapy on overall survival in colorectal cancer patients, aiming to guide clinical decisions on optimal chemotherapy timing. (J Gastrointest Cancer)
LIVING WITH CRC
Systematic review evaluates treatments for bowel dysfunction after colorectal cancer surgery
Eight studies examined pharmacological therapies including serotonin receptor antagonists, herbal medicines, diazepam, and Botulinum A toxin for managing bowel dysfunction following sphincter-preserving surgeries. (Adv Pharm Bull)
LIVING WITH CRC
Traditional Chinese Medicine formula shows benefit for chemotherapy side effects in real-world study
In a propensity-matched analysis of 178 colorectal cancer patients, those receiving a standardized TCM formula alongside fluoropyrimidine chemotherapy had reduced gastrointestinal toxicity and improved quality of life compared to conventional care alone. (Explore)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Deficient mismatch repair is a distinct feature of early-onset CRC in Chinese cohort
Among 4,159 colorectal cancer cases at West China Hospital, early-onset CRC (diagnosed before age 50) showed higher rates of deficient mismatch repair compared to late-onset disease. (Int J Cancer)
South Dakota sees shifting trends in early-onset CRC incidence by race
Analysis of 2007-2022 cancer registry data shows the White population's early-onset CRC incidence rose to 9.6 per 100,000 in 2018-2022, surpassing the American Indian rate and reversing historical patterns. (S D Med)

Research continues to advance our understanding of colorectal cancer across all stages and populations.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest